Elevai Biosciences has engaged KCRN Research to support the Company’s initial efforts to prepare for an Investigational New Drug application to the FDA for EL-22 in the treatment of obesity and muscle ...
KAWASAKI, Japan, December 12, 2024--(BUSINESS WIRE)--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587) today ...
EL-22 is a novel myostatin asset for the potential treatment of obesity in combination with existing GLP-1 medicines The Investigational New Drug application is planned for submission to the U.S. Food ...
Inhibiting a growth factor that keeps muscles from getting too big may optimize recovery of injured soldiers, researchers say. Bone biologists are studying two myostatin inhibitors in mice with limb ...
NEWPORT BEACH, Calif. - Elevai Biosciences Inc., part of Elevai Labs Inc. (NASDAQ: ELAB), is advancing its efforts to seek regulatory approval for a new obesity treatment, EL-22, by engaging with KCRN ...
To obtain a myostatin propeptide that would have a more potent inhibitory effect on myostatin, we mutated the propeptide at the BMP-1/TLD cleavage site by replacing the aspartate at position 76 by an ...
It is noteworthy that Follistatin generates the FS-344 and FS-317 isoforms by alternative splicing. By subsequent cleavage FS-344 and FS-317 give rise to FS-315 and FS-288 polypeptides respectively; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback